Frontlight ResearchEarly access
TerminatedPhase 2
Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT)
Key facts
- Who runs it
- David J. Gagnon
- Where
- Portland, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 53 people enrolled
- Started
- 20 Aug 2021
- Ended
- 1 Nov 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Standard of care without prophylaxis
- Antibiotic prophylaxis
- Record updated
- 17 April 2025
- Why it stopped
- Lapse in funding
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- ≥18 years of age
- Comatose (do not follow simple verbal commands)
- Have any initial heart rhythm (shockable or non-shockable)
- OHCA including the emergency department
Who cannot take part
- Interval >6 hours from ICU admission to study drug receipt
- Clinical bacterial infection prior to hospital admission defined as any one of the following:; Infectious prodrome preceding OHCA; Active course of antibiotics for infection prior to admission; Active infection documented in the electronic medical record; Family or surrogate endorsement of an active infection
- In-hospital cardiac arrest
- Preexisting terminal disease making 180-day survival unlikely
- Name on opt-out list
- Refused informed consent
- Emergent coronary artery bypass grafting
- Anaphylaxis or angioedema to beta-lactam antibiotics (i.e., cephalosporins or penicillins)
- Under legal guardianship or prisoner
- Known colonization with methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant enterococcus (VRE)
Where in United States
- Maine Medical CenterPortland, United States
About the trial
What the trial wants to find out
Randomized-controlled trial and microbiome assessment to understand the risk-to-benefit ratio of prophylactic antibiotics (Ceftriaxone) vs placebo in patients with pneumonia and inflammation after cardiac arrest outside the hospital.
The 2 groups in the trial
- No prophylaxis (placebo)Existing treatment, for comparison
Standard care without antibiotic prophylaxis and treatment of infection if clinically warranted. Administer antibiotics in response to infection.
Treatment: Standard of care without prophylaxis
- ProphylaxisTreatment being tested
Antibiotic prophylaxis for 3 days. Antibiotic prophylaxis with Ceftriaxone 2 gm IV q12h for 3 days.
Treatment: Antibiotic prophylaxis
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT): a Randomized-controlled Trial and Microbiome Assessment
- Publications
- Ceftriaxone to Prevent Early-Onset Pneumonia in Comatose Patients Following Out-of-Hospital Cardiac Arrest: A Pilot Randomized Controlled Trial and Resistome Assessment (PROTECT).Chest, 2026
- Ceftriaxone to PRevent pneumOnia and inflammaTion aftEr Cardiac arresT (PROTECT): study protocol for a randomized, placebo-controlled trial.Trials, 2022
- Record updated
- 17 April 2025